clinical trial · NCT05170828
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.·phase1·withdrawn
Acute LeukemiaMyelodysplastic SyndromesT-lymphoblastic LymphomaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaAcute Biphenotypic LeukemiaAcute Undifferentiated LeukemiaCyclophosphamideFludarabineTotal Body IrradiationBusulfanMesnaSirolimusMycophenolate MofetilFilgrastim
brief summary
Multicenter single arm study to assess the safety and efficacy of allogeneic transplantation using cryopreserved bone marrow from deceased MMUD and PTCy, sirolimus and MMF for GVHD prophylaxis.
started
Sep 1, 2022
primary completion
Mar 1, 2024
completion
Nov 1, 2024
last updated
Feb 24, 2026
official title
PRESERVE: A Multi-Center Trial Using Banked, Cryopreserved HLA-Mismatched Unrelated Donor Bone Marrow and Post-Transplantation Cyclophosphamide in Allogeneic Transplantation for Patients With Hematologic Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol